Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Discusses Interchangeability And Adalimumab

Regulatory Chief Voices Support For Making All FDA-Approved Biosimilars Interchangeable

Executive Summary

As Samsung Bioepis seeks a US interchangeability designation for its Organon-partnered Hadlima adalimumab biosimilar, the firm’s regulatory affairs chief Byoungin Jung talks to Generics Bulletin about the significance of interchangeability for US biosimilars – and the firm’s support for legislative efforts to have all US approved biosimilars automatically designated as interchangeable.

You may also be interested in...



Humira Horsepower: AbbVie’s Brand Retains 98% US Market Share

Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market.

Cimerli Interchangeable Biosimilar Approved Without Switching Data

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.

Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval

Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel